Radioactive drug aims to supercharge cancer immunotherapy

NCT ID NCT07197671

Recruiting now Disease control Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This early-phase trial tests a radioactive drug called Y-NM600 in people with metastatic cancer who are already receiving immunotherapy (anti-PD-1 or anti-PD-L1). The goal is to see if adding Y-NM600 is safe and can make the immunotherapy work better. Up to 60 participants will be followed for about 9 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Y-NM600 (a radioactive drug that targets tumors)
What this could lead to: If it works, this could make existing immunotherapies work better for people with metastatic cancer, potentially slowing disease progression.
What could go wrong: This is an early Phase 1 trial with only 60 participants, so safety and effectiveness are not yet proven. There is a risk of side effects from the radioactive drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

UW Carbone Cancer Center
RECRUITING

Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.